A proposed rule that would change FDA oversight of laboratory-developed tests may have negative effects on cancer care and innovation in oncology, according to critics. A proposed rule that would change FDA oversight of laboratory-developed tests may have negative effects on cancer care and innovation in oncology.
A proposed rule that would change FDA oversight of laboratory-developed tests may have negative effects on cancer care and innovation in oncology, according to critics. A proposed rule that would change FDA oversight of laboratory-developed tests may have negative effects on cancer care and innovation in oncology.